With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.
Synthesis of ethyl 2-acetyl-3-(3-bromo-5-fluorophenyl)-4-(4-chlorophenyl)-4-oxobutanoate To a solution of ethyl-2-(3-bromo-5-fluorobenzylidene)-3-oxobutanoate (46.8 g, 148.5 mmol) and 4-chlorobenzaldehyde (21.4 g, 152.2 mmol) in ethanol (240 mL) was added triethylamine (31 mL, 222 mmol). Nitrogen gas was bubbled through the mixture for 5 min and 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (6 g, 22 mmol) was then added. The mixture was heated to 70 C. for 2 h under a nitrogen atmosphere. The solvent was removed under vacuum and the residual crude was dissolved in EtOAc (700 mL) and washed with 1 M aqueous HCl (130 mL), water (2*150 mL) and brine (2*20 mL). The organic extract was dried over MgSO4, filtered and concentrated under vacuum to give ethyl 2-acetyl-3-(3-bromo-5-fluorophenyl)-4-(4-chlorophenyl)-4-oxobutanoate as an orange gum (73.1 g) which was used without purification. LCMS (ESI) [M+Na]+=477.0/479.0
4568-71-2, As the paragraph descriping shows that 4568-71-2 is playing an increasingly important role.
Reference£º
Patent; Unity Biotechnology; Beausoleil, Anne-Marie; Hudson, Ryan; (111 pag.)US2019/330250; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI